European annals of allergy and clinical immunology最新文献

{"title":"Dupilumab to induce tolerance to SLIT-Melocotón®.","authors":"M S Zamarro Parra, Y Petryk Petryk, S San Román Sirvent, C Navarro Garrido, A I Escudero Pastor, J C Miralles López, A Carbonell Martínez","doi":"10.23822/EurAnnACI.1764-1489.280","DOIUrl":"10.23822/EurAnnACI.1764-1489.280","url":null,"abstract":"<p><strong>Summary: </strong>Food allergy is an increasing problem for population, and treatments inducing tolerance using sublingual immunotherapy is currently under study. Our aim as allergists is to achieve tolerance to sublingual allergen specific immunotherapy with sublingual immunotherapy (SLIT-peach). We present a case report consisting of a 40-year-old woman with anaphylactic reactions after eating fruit and other plant-foods due to sensitization to nonspecific lipid transfer proteins (nsLTP). Her diagnose was LTP-syndrome. This protein is the main pannallergen in our area and causes crossed reaction to multiple plant foods. The principal allergen in this syndrome is rPru p3, present in peach and most vegetables, fruits, nuts and grains. Serum specific IgE levels were performed using microarrays and positive for seven nsLTPs: rAra h9, rCor a8, nJug r3, rPru p3, rTri a 14, nArt v3 and rPla a3. Immediate reaction to SLIT in the fourth month of maintenance-dose led us to interrupt pru p3 immunotherapy. Immediate reaction to omalizumab in the fourth dose in hospital consisting in anaphylaxis prompted us to switch to dupilumab. After four months with this monoclonal antibody, we reintroduced sublingual immunotherapy with pru p3 SLIT-peach^® achieving maintenance dose of four drops a day with no clinical reactions. SLIT-peach^® in our patient is crucial for her due to her restricted diet, the severity of reactions and lack of quality of life measured by Europevall questionary. There are no cases reported for dupilumab in this use.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"137-140"},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9072718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Probiotics, prebiotics and food allergy: a review.","authors":"J F Ribeiro, C Pedrosa","doi":"10.23822/EurAnnACI.1764-1489.319","DOIUrl":"10.23822/EurAnnACI.1764-1489.319","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> The review was structured in the following sections: 1) Cow's Milk Proteins Allergy (CMA), 2) Food Allergy to Peanuts and 3) Prevention of Food Allergy. In CMA, studies indicate that extensively hydrolyzed casein formula supplemented with <i>Lactobacillus Rhamnosus</i> GG aids in acquiring tolerance to cow's milk proteins, resolving gastrointestinal symptoms and preventing of other allergic manifestations. In peanut oral immunotherapy (OI), supplementation with <i>Lactobacillus Rhamnosus</i> CGMCC 1.3724 appears to promote sustained desensitization. However, the evidence supporting probiotics for preventing food allergies lacks robustness. Current evidence supports the use of oligosaccharides from breast milk in the first months of life for preventing atopic dermatitis, FA and asthma <b>Methods.</b> A PubMed/Medline search was carried out on articles published between 2011 and 2021 with the following query: (\"Food Hypersensitivity\"[Mesh]) AND ((\"Probiotics\"[Mesh]) OR (\"Prebiotics\"[Mesh])). Subsequently, the titles and abstracts were analysed and selected according to established criteria. After full reading of these articles, 54 were included and a narrative review was performed. <b>Results.</b> The review was structured in the following sections: 1) Cow's Milk Proteins Allergy (CMA), 2) Food Allergy to Peanuts and 3) Prevention of Food Allergy. In CMA, studies indicate that extensively hydrolyzed casein formula supplemented with <i>Lactobacillus Rhamnosus</i> GG aids in acquiring tolerance to cow's milk proteins, resolving gastrointestinal symptoms and preventing of other allergic manifestations. In peanut oral immunotherapy (OI), supplementation with <i>Lactobacillus Rhamnosus</i> CGMCC 1.3724 appears to promote sustained desensitization. However, the evidence supporting probiotics for preventing food allergies lacks robustness. Current evidence supports the use of oligosaccharides from breast milk in the first months of life for preventing atopic dermatitis, FA and asthma. <b>Conclusions.</b> The potential of probiotics to be used as therapeutic adjuvants in CMA and peanut OI is promising. However, there is inconsistency regarding the type of probiotic, the dose and duration of supplementation. Further studies are needed to clarify the role of probiotics and prebiotics in FA.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"99-110"},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138487066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic rhinosinusitis with nasal polyposis and biological agents: the ARIA-ITALY Survey.","authors":"C Lombardi, G Passalacqua, F Menzella, R F Mauritz Canevari, G Danesi, A M Pusateri, M Carone, C Vancheri, F Di Marco, C Micheletto, G Manzotti, M Di Gioacchino, M B Bilò, M Gelardi, G Senna, G W Canonica","doi":"10.23822/EurAnnACI.1764-1489.338","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.338","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Chronic rhinosinusitis (CRS) is an inflammatory disease that affects the nasal mucosa and the paranasal sinuses. CRS can be associated by nasal polyposis (CRSwNP phenotype) in up to 30% of patients and it is frequently associated with bronchial asthma. CRSwNP shows predominantly an underlying activation of type 2 inflammatory pathways with the involvement of eosinophils, IgE, interleukin (IL)-4, IL-5 and IL-13. Biological drugs that target these inflammatory cytokines are currently a therapeutic option recognized by guidelines for the treatment of uncontrolled form of the disease. <b>Methods.</b> As part of the activity of the \"ARIA-Italy\" working group, a panel of 255 Italian Ear, Nose and Throat (ENT) specialists, pneumologists and immuno-allergologists actively participated in this national survey and answered a series of questions geared toward understanding the main criteria for patient characterization and therapeutic decision, highlighting multidisciplinarity, and the implementation of the management of CRSwNP patients, as a part of the precision medicine concept and the appropriate use of the biologicals. <b>Results.</b> Two hundred and fifty-five experts and specialists participated in the survey. <b>Conclusions.</b> The results of this survey obtained from an extensive number of active specialists throughout Italy allow some important concluding remarks to be drawn. The main points of agreement were that multidisciplinary care teams provide many benefits but that, once the team is established, meetings and communication between members must be coordinated. Finally, the dissemination of national disease registries and the continuous updating of guidelines and position papers related to CRSwNP and comorbidities should be encouraged.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140293248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The autologous serum skin test (ASST) predicts the response to anti-IgE treatment in Chronic Spontaneous Urticaria patients: a prospective study.","authors":"A Palladino, F Villani, E Pinter, M Visentini, R Asero","doi":"10.23822/EurAnnACI.1764-1489.337","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.337","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Chronic spontaneous urticaria (CSU), characterized by recurrent itchy wheals and angioedema for > 6 weeks, is a quite common disease that may heavily impair the quality of life. Omalizumab, an anti-IgE mAb, has much improved the management of CSU but patients' response to the drug may vary and predictive markers are still largely missing. We investigated the predictive value of the autologous serum skin test (ASST) on omalizumab response. <b>Methods.</b> 15 patients with severe CSU eligible for omalizumab treatment were prospectively studied submitting them to ASST and to complete blood count, D-dimer, anti-thyroid peroxidase antibodies, and total IgE measurement before the start of the treatment. <b>Results.</b> 14/15 (93%) responded brilliantly to omalizumab at 3 months assessment. 7 responded in less than 1 month (\"early responders\") and 7 only after multiple administrations (\"late responders\"). Of 9 patients scoring positive on ASST, 7 (78%) were late, and 2 (22%) early responders to omalizumab (p = 0.021). Of 6 patients scoring negative on ASST, 5 were early omalizumab responders and 1 did not respond. The PPV and NPV of the ASST for a \"late\" response to omalizumab were 78% and 100%, respectively. Total IgE were significantly higher in early responders. <b>Conclusions.</b> Although larger prospective studies are needed to confirm these results, this study confirms previous retrospective investigations that the positive ASST appears to predict a slow response to omalizumab in CSU patients.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140119169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges in egg allergy: a retrospective look at the utility of cut-off values.","authors":"P Botelho Alves, H Pires Pereira, I Carrapatoso, G Loureiro, I Farinha, M Lucena, T Freitas, A Todo Bom","doi":"10.23822/EurAnnACI.1764-1489.336","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.336","url":null,"abstract":"","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140119168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Food-dependent exercise-induced allergic reactions in Lipid Transfer Protein (LTP) hypersensitive subjects: new data and a critical reappraisal.","authors":"E Scala, V Villella, R Asero","doi":"10.23822/EurAnnACI.1764-1489.334","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.334","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Lipid transfer protein is the main cause of both primary food allergy and food-dependent exercise-induced allergic reactions (FDEIAR) in Italy. What characterizes LTP-hypersensitive patients with FDEIAR is still unclear. We investigated the key characteristics of LTP-hypersensitive patients with or without FDEIAR in a large cohort of individuals sensitized to this allergen. <b>Methods.</b> 1,203 food-allergic patients, diagnosed on the basis of unequivocal clinical history and presence of circulating food allergen-specific IgE were studied. Serum IgE reactivity was assessed using the Allergen ExplorerALEX^® system (Macroarray Diagnostics, Vienna, Austria). Association of specific IgE reactivities with FDEIAR was investigated, and patients with and without FDEIAR sensitized to LTP were compared. <b>Results.</b> 116 subjects (9.6%) had FDEIAR. Among these, 77 (66.3%) were LTP-reactors and 16 (13.8%) were sensitized to Tri a 19 (omega-5-gliadin). Different LTPs and omega-5-gliadin emerged as the sole allergens clearly associated with FDEIAR. Severity of allergic reactions was paralleled the level of specific IgE to LTPs. Patients with FDEIAR showed significantly lower IgE levels than their counterparts with food allergy at rest, and displayed nearly identical IgE levels regardless of the severity of allergic reactions induced by exercise. <b>Conclusions.</b> FDEIAR are associated with specific allergens. Specific IgE levels in LTP-hypersensitive patients with FDEIAR show an intermediate titer between those simply sensitized and those showing classic food allergy.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140038974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The clinical and laboratory findings of infants with atopic dermatitis during diagnosis and follow-up.","authors":"A Chousein, H Duman Senol, E Ece Özdoğru, S Eren Akarcan, T Tuncel","doi":"10.23822/EurAnnACI.1764-1489.281","DOIUrl":"10.23822/EurAnnACI.1764-1489.281","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Atopic dermatitis is a chronic disease that affects patient and parents life worsely. What time will the patient go into remission is not known. Therefore, clinical and laboratory indicators that can indicate remission are needed. <b>Materials and Methods.</b> The study was conducted in İzmir Health Sciences University, Tepecik Training and Research Hospital. The clinical and laboratory data of patients between January 2014 and December 2019 were scanned from the patient records and the hospital data system. <b>Results.</b> 102 patients with a median age of 8 (min 2- max 24) months were included in the study. The median age of onset of the symptoms was 3 (min 1-max 21) months. The patients most frequently (85.2%) presented with eczema and lesions were most common (60.7%) in the extremities. Most of the patients (56.9%) had mild dermatitis. In the 6^th month, 26.5% who continued follow-up had clinical improvement. Food allergy was present in 33.3% of the patients. The most common food allergen was egg (52.9%). Food allergy was associated with the severity of atopic dermatitis (p = 0.033), and the symptoms started earlier (p = 0.002). There is no relationship between the severity of atopic dermatitis and gender, family history, presence of additional atopic disease, response to treatment, total IgE and eosinophil count (p > 0.05); however, it was determined that the symptoms started earlier in patients with moderate/severe atopic dermatitis (p = 0.002). <b>Conclusions.</b> Food allergy is more common in the early-onset and moderate/severe atopic dermatitis. Accurate diagnosis of food allergy is necessary to increase the success of treatment and to prevent unnecessary diets.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"71-78"},"PeriodicalIF":2.3,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9072719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acetylsalicylic acid desensitization in an allergic pregnant woman post-vascular scaffolds implantation.","authors":"F Rivolta, A Chiei Gallo, A Sangalli, V Pravettoni","doi":"10.23822/EurAnnACI.1764-1489.276","DOIUrl":"10.23822/EurAnnACI.1764-1489.276","url":null,"abstract":"<p><strong>Summary: </strong>The use of acetylsalicylic acid (ASA) desensitization for patients with coronary artery disease (CAD) is growing, but no data are available on desensitization protocol in patients with ASA sensitivity and CAD during pregnancy. This case report shows that ASA desensitization protocol during pregnancy could be safe and effective in a tertiary centre with a multidisciplinary team.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"86-88"},"PeriodicalIF":2.3,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10705431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current update on anaphylaxis: anaphylaxis management in recent guidelines.","authors":"D Antolín-Amérigo, C Vidal-Albareda, D González de Olano, B de la Hoz-Caballer","doi":"10.23822/EurAnnACI.1764-1489.306","DOIUrl":"10.23822/EurAnnACI.1764-1489.306","url":null,"abstract":"<p><strong>Summary: </strong>Anaphylaxis is a potentially fatal hypersensitivity reaction but frequently underrecognized. Although its incidence rates vary according to geographical location, it seems clear that there has been a general increase in recent years, either because of greater recognition of this entity or because it is progressing proportionally to the presence of allergic diseases in the world. The development of anaphylaxis management guidelines adapted to local or regional needs seems of utmost importance. Furthermore, it is necessary to assess their implementation and their positive effect regarding diagnosing and treating anaphylaxis. In this review we explore the currently existing definitions of anaphylaxis and its epidemiology, the potential triggers of anaphylaxis and guideline recommendations in terms of diagnosis and management, proposing a novel anaphylaxis calculator and reviewing the current scoring methods for anaphylactic episodes.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"51-64"},"PeriodicalIF":2.3,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9817806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic accuracy of patch testing based in clinical response to contact allergen restrictions in allergic contact dermatitis.","authors":"J Sánchez, L Álvarez, S Die, J Miquel-Miquel, M Velásquez","doi":"10.23822/EurAnnACI.1764-1489.331","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.331","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Patch testing (PT) is used to identify substances that cause allergic contact dermatitis (ACD). However, the clinical effects of allergen restrictions following PT have not been thoroughly investigated. This study aims to assess the diagnostic accuracy of PT in patients suspected of having ACD. <b>Methods.</b> Prospective study. PT were performed in patients with clinical diagnosis of ACD. Patients with a positive PT (case group) had a strict restriction of the suspected substance for one month. In patients with negative patch testing (control group), allergen restriction was based in clinical history. Clinical reduction (CR) of at least 50% in disease activity (CR50%) after one month of allergen restriction was considered clinically relevant. Total control was defined as clinical reduction of at least 90% (CR90%). <b>Results.</b> From 400 patients, 66.2% had a positive PT. The sensitivity of PT to identify CR50% was 84%, specificity 47%, PPV 53%, and NPV 81%. Only 10.5% of patients achieved CR90%. <b>Conclusions.</b> The PT had moderate diagnostic accuracy. It could be useful as a screening, but a positive result should be confirmed with controlled allergen restriction. The low number of patients who achieved a 90% CR invites to reconsider the allergens included in PT and the mechanistic processes of the disease.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139905331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}